Tests VB15010 tablets in adults with advanced solid tumors
Tests VB15010, a PARP1 inhibitor pill, for safety in advanced solid tumors.
Plain-language title generated from the registry record
Registry title: Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Key facts
- Where
- Jinan, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06819215, who can take part
Where in China
- Cancer Hospital of Shandong First Medical UniversityJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
- Trial code
- NCT06819215
- Record updated
- 11 February 2025
- Original description
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.Read full original descriptionShow less
Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Inclusion: Age ≥ 18 at the time of screening; Histological or cytological confirmation of advanced malignancy ; Progressive cancer at the time of study entry; Adequate organ and marrow function as defined by the protocol; Homologous recombination repair gene mutation.
Exclusion: Major surgery within 4 weeks of the first dose of study treatment; Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded; Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).